Bavarian Nordic A/S (OTCMKTS:BVNRY) Hits New 12-Month Low - Here's Why

Bavarian Nordic A/S (OTCMKTS:BVNRY - Get Free Report) shares reached a new 52-week low during trading on Monday . The stock traded as low as $6.60 and last traded at $6.84, with a volume of 10147 shares traded. The stock had previously closed at $6.90.

Bavarian Nordic A/S Price Performance

The firm has a 50 day moving average price of $7.75 and a 200-day moving average price of $8.95. The firm has a market capitalization of $1.77 billion, a price-to-earnings ratio of 10.84 and a beta of 1.55.

Bavarian Nordic A/S (OTCMKTS:BVNRY - Get Free Report) last posted its earnings results on Wednesday, March 5th. The company reported $0.47 earnings per share for the quarter, topping the consensus estimate of $0.40 by $0.07. The firm had revenue of $299.48 million during the quarter, compared to analysts' expectations of $264.06 million. Bavarian Nordic A/S had a return on equity of 10.65% and a net margin of 18.33%. Equities research analysts predict that Bavarian Nordic A/S will post 0.67 earnings per share for the current year.

About Bavarian Nordic A/S

Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; and Ebola vaccine under the MVABEA name.